Saturday 17 October 2026
Export RCUS’s income statement to Excel — free account
Arcus Biosciences, Inc.
RCUS Healthcare Biotechnology
Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024. In the quarter to June 2026, revenue fell 74.4%, EPS was flat, free cash flow grew 10.5% and total debt rose 4.12%, each against the same quarter a year earlier.
22.12
0.70
−3.07%
Follow RCUS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
33.23 | 11.48 | 10.36 | 6.04 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(32.67) | (19.63) | (21.33) | (14.93) | |
P/B ratio |
8.38 | 5.17 | 4.06 | 3.32 | |
Price to Tangible BV |
8.38 | 5.17 | 4.06 | 3.32 | |
EV/Sales |
28.09 | 8.42 | 6.79 | 2.98 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.93) | (4.07) | (3.48) | (1.55) | |
EV/FCF |
(6.90) | (4.05) | (3.47) | (1.54) | |
Quick Ratio |
3.73 | 3.95 | 4.29 | 3.58 | |
Current Ratio |
3.82 | 4.04 | 4.36 | 3.65 | |
Net Debt/EBITDA |
6.26 | 5.35 | 7.74 | 5.13 | |
Debt/Assets |
10.93% | 10.03% | 8.69% | 10.06% | |
Debt/Equity |
0.22 | 0.19 | 0.16 | 0.22 | |
Asset Turnover |
0.12 | 0.22 | 0.22 | 0.22 | |
Operating CF/Net income |
1.31 | 1.08 | 1.13 | 0.72 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(32.00) | (44.67) | (57.00) | (47.33) | |
Research and Development Expense of Revenue |
275.61% | 717.65% | 366.67% | 542.31% | |
Selling, General and Administrative Expense of Revenue |
58.54% | 170.59% | 78.79% | 103.85% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
36.59% | 111.76% | 45.45% | 53.85% | |
Graham Net Nets |
0.08 | 0.14 | 0.20 | 0.22 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(12.65%) | (14.72%) | (13.85%) | (25.29%) | |
Free Cash Flow Yield |
(12.24%) | (18.09%) | (18.91%) | (32.04%) | |
Revenue per Share |
0.33 | 0.14 | 0.31 | 0.24 | |
Operating CF per Share |
(0.94) | (1.10) | (1.12) | (0.91) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.94) | (1.10) | (1.13) | (0.91) | |
Cash per Share |
5.57 | 6.56 | 9.13 | 7.80 | |
Shareholders Equity per Share |
3.68 | 4.18 | 5.88 | 4.09 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.68 | 4.18 | 5.88 | 4.09 | |
Free Cash Flow |
(119.00) | (138.00) | (121.00) | (97.00) | |
Working Capital |
558.00 | 635.00 | 776.00 | 622.00 | |
Capital Expenditures |
— | — | (1.00) | 0.00 | |
Net Current Asset Value |
296.00 | 371.00 | 499.00 | 319.00 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.03 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
25.50 | 9.00 | 15.50 | 13.50 | |
Average Payables |
31.50 | 30.50 | 30.00 | 27.50 | |
Average Assets |
999.50 | 1,076.50 | 1,144.50 | 1,113.00 | |
Average Common Equity |
506.50 | 527.50 | 558.00 | 500.50 |
Columns are period end dates